Article
Circulating Proteoglycan Endocan Mediates EGFR-Driven Progression of Non-Small Cell Lung Cancer.
Cancer research - 15 Aug 2020
Yang Yi-Chieh, Pan Ke-Fan, Lee Wei-Jiunn, Chang Jer-Hwa, Tan Peng, Gu Chia-Chi, Chang Wei-Min, Yang Shun-Fa, Hsiao Michael, Hua Kuo-Tai, Chien Ming-Hsien
Abstract excerpt
Although new generations of EGFR-tyrosine kinase inhibitors (EGFR-TKI) have been developed for the treatment of patients with non-small cell lung cancer (NSCLC) with EGFR-mutant tumors, TKI resistance often returns as a result of additional EGFR mutations. In addition to seeking for next-generation EGFR-TKI, developing novel EGFR-targeting strategies may hold the key to overcome the vicious cycle of TKI...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.